Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
ALGS(NASDAQ:ALGS) SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced six presentations, including three oral presentations, at the 2025 International HBV Meeting, being held September 8 – 12, 2025 in Berlin, Germany.
Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
ALGS(NASDAQ:ALGS) SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025.
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
ALGSSOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Ramón Polo, PharmD, PhD, MBA as Senior Vice President, Head of Global Regulatory Affairs, effective immediately.
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ALGSSOUTH SAN FRANCISCO, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 42,300 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on August 12, 2025 (the “Grant Date”), in connection with the commencement of employment.
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
ALGSSOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing in the Phase 2 B-SUPREME study of its investigational compound ALG-000184 has been initiated in subjects with chronic hepatitis B virus (HBV) infection.
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
ALGSSOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the second quarter 2025.
Aligos Therapeutics Q1 EPS $(2.11) Beats $(2.74) Estimate, Revenue $311.00K Miss $333.33K Estimate
ALGSAligos Therapeutics's Earnings Outlook
ALGSAligos Therapeutics Announces Eight Abstracts Accepted For Presentation At EASL Congress 2025 In Amsterdam , Netherlands
ALGSHC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $70 Price Target
ALGSHC Wainwright & Co. Maintains Buy on Aligos Therapeutics, Lowers Price Target to $70
ALGSNasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday?
ALGSStocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir Technologies, Inc.
Aligos Therapeutics Q4 EPS $(13.08) Misses $(2.30) Estimate, Sales $629.00K Beat $433.33K Estimate
ALGSEarnings Scheduled For March 10, 2025
ALGSAligos Therapeutics Announces $105M Private Placement Financing; Proceeds Expected To Fund The Start Of Its ALG-000184 Phase 2 Study
ALGSHow Is The Market Feeling About Aligos Therapeutics?
ALGSAligos Therapeutics Shares Resume Trade
ALGSAligos Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 1.54%
ALGSAligos Therapeutics Presents Data From One Late-Breaker Oral And 3 Poster Presentations At The American Association For The Study Of Liver Disease's The Liver Meeting 2024; 12-Weeks Of Once Daily ALG-055009 Treatment In MASH Patients Met The Primary Endpo
ALGSAligos Therapeutics Q3 2024 GAAP EPS $(3.07) Misses $(2.15) Estimate, Sales $1.269M Beat $333.333K Estimate
ALGSAligos Therapeutics Completes Enrollment In The ALG-055009 Phase 2a HERALD Study For The Treatment Of MASH
ALGSAligos Therapeutics Q1 EPS $(0.84) Misses $(0.73) Estimate
ALGSPreview: Aligos Therapeutics's Earnings
ALGSAligos Therapeutics (NASDAQ:ALGS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement.
Analysts estimate that Aligos Therapeutics will report an earnings per share (EPS) of $-0.73.
